Staphylococcus aureus manganese transport protein c is a highly conserved cell surface protein that elicits protective immunity against s. aureus and staphylococcus epidermidis

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1688-1696

  Anderson, Annaliesa S ^a   Scully, Ingrid L ^a   Timofeyeva, Yekaterina ^a   Murphy, Ellen ^a   McNeil, Lisa K ^a   Mininni, Terri ^a   Nuñez, Lorna ^a   Carriere, Marjolaine ^a   Singer, Christine ^a   Dilts, Deborah A ^a   Jansen, Kathrin U ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM PHOSPHATE; CELL SURFACE PROTEIN; MANGANESE BINDING SURFACE LIPOPROTEIN; MANGANESE TRANSPORT PROTEIN C; MANGANESE TRANSPORT PROTEIN C ANTIBODY; MANGANESE TRANSPORT PROTEIN C VACCINE; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BACTEREMIA; BACTERIAL CELL; BACTERIAL LOAD; GENETIC CONSERVATION; IMMUNITY; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPEATED DRUG DOSE; RESPIRATORY BURST; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BACTERIAL LOAD; BACTERIAL PROTEINS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; MEMBRANE PROTEINS; MICE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME;

EID: 84861073276     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis272     Document Type: Article

References (28)

1. Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74:2215-23.
2. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184:1572-80. (Pubitemid 33139743)
3. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006; 103:16942-7. (Pubitemid 44737357)
4. Gill SR, Fouts DE, Archer GL, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol 2005; 187:2426-38. (Pubitemid 40389140)
5. Piette A, Verschraegen G. Role of coagulase-negative staphylococci in human disease. Vet Microbiol 2009; 134:45-54.
6. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002; 2:677-85. (Pubitemid 35265063)
7. Broughan J, Anderson R, Anderson AS. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert Rev Vaccines 2011; 10:695-708.
8. Burman JD, Leung E, Atkins KL, et al. Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus. J Biol Chem 2008; 283:17579-93.
9. Stauff DL, Skaar EP. The heme sensor system of Staphylococcus aureus. Contrib Microbiol 2009; 16:120-35.
10. Horsburgh MJ, Wharton SJ, Cox AG, Ingham E, Peacock S, Foster SJ. MntR modulates expression of the PerR regulon and superoxide resistance in Staphylococcus aureus through control of manganese uptake. Mol Microbiol 2002; 44:1269-86. (Pubitemid 34595758)
11. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME. Identification of Staphylococcus aureus proteins recognized by the antibodymediated immune response to a biofilm infection. Infect Immun 2006; 74:3415-26. (Pubitemid 43794532)
12. Cockayne A, Hill PJ, Powell NB, Bishop K, Sims C, Williams P. Molecular cloning of a 32-kilodalton lipoprotein component of a novel iron-regulated Staphylococcus epidermidis ABC transporter. Infect Immun 1998; 66:3767-74. (Pubitemid 28347835)
13. Sellman BR, Howell AP, Kelly-Boyd C, Baker SM. Identification of immunogenic and serum binding proteins of Staphylococcus epidermidis. Infect Immun 2005; 73:6591-600. (Pubitemid 41368825)
14. Murphy E, Lin SL, Nunez L, et al. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum Vaccin 2011; 7 Suppl:51-9.
15. Heilmann C, Gerke C, Perdreau-Remington F, Gotz F. Characterization of Tn917 insertion mutants of Staphylococcus epidermidis affected in biofilm formation. Infect Immun 1996; 64:277-82. (Pubitemid 26009366)
16. Clarke SR, Brummell KJ, Horsburgh MJ, et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 2006; 193:1098-108.
17. Johne B. Epitope mapping by surface plasmon resonance in the BIAcore. Mol Biotechnol 1998; 9:65-71. (Pubitemid 28387213)
18. Limbago B, Fosheim GE, Schoonover V, et al. Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis. J Clin Microbiol 2009; 47:1344-51.
19. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961; 50:161-8.
20. Jakubovics NS, Jenkinson HF. Out of the iron age: new insights into the critical role of manganese homeostasis in bacteria. Microbiology 2001; 147:1709-18. (Pubitemid 32684914)
21. Raedler MD, Heyne S, Wagner E, et al. Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen. Clin Vaccine Immunol 2009; 16:739-48.
22. Harro C, Betts R, Orenstein W, et al. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol 2010; 17:1868-74.
23. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, Missiakas DM. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J 2009; 23:3393-404.
24. Karavolos MH, Horsburgh MJ, Ingham E, Foster SJ. Role and regulation of the superoxide dismutases of Staphylococcus aureus. Microbiology 2003; 149:2749-58. (Pubitemid 37279250)
25. Tseng HJ, Srikhanta Y, McEwan AG, Jennings MP. Accumulation of manganese in Neisseria gonorrhoeae correlates with resistance to oxidative killing by superoxide anion and is independent of superoxide dismutase activity. Mol Microbiol 2001; 40:1175-86. (Pubitemid 32574984)
26. Johnston RB Jr, Keele BB Jr, Misra HP, et al. The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes. J Clin Invest 1975; 55:1357-72. (Pubitemid 8036498)
27. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6. (Pubitemid 34441740)
28. Nanra JS, Timofeyeva Y, Buitrago SM, et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 2009; 27:3276-80.